Related content

The tyrosine kinase inhibitor STI571, like interferon- , preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

By Marley S.B.   Deininger M.W.N.   Davidson R.J.   Goldman J.M.   Gordon M.Y.  

Experimental Hematology, Vol. 28, Iss. 5, 2000-05 ,pp. : 551-557

Elsevier

Access to resources Recommend Favorite

Bilateral Toxoplasma Retinochoroiditis in a Patient with Chronic Myeloid Leukemia Treated with Imatinib Mesylate

By Basu Soumyava   Das Taraprasad   Biswas Ghanshyam  

Ocular Immunology and Inflammation, Vol. 18, Iss. 1, 2010-01 ,pp. : 64-65

Informa Healthcare

Access to resources Recommend Favorite

Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab–bendamustine

By García-Muñoz Ricardo   García Diana   Roldán-Galiacho Verónica   Merchante-Andreu Miriam   Campeny-Najara Andrea   Rabasa Pilar  

Annals of Hematology, Vol. 93, Iss. 4, 2014-04 ,pp. : 699-702

Springer Publishing Company

Access to resources Recommend Favorite

Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors

By Yamamoto-Yamaguchi Y.   Okabe-Kado J.   Kasukabe T.   Honma Y.  

Experimental Hematology, Vol. 29, Iss. 5, 2001-05 ,pp. : 582-588

Elsevier

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite